CL2020002613A1 - Receptores quiméricos de dll3 y métodos para su uso - Google Patents

Receptores quiméricos de dll3 y métodos para su uso

Info

Publication number
CL2020002613A1
CL2020002613A1 CL2020002613A CL2020002613A CL2020002613A1 CL 2020002613 A1 CL2020002613 A1 CL 2020002613A1 CL 2020002613 A CL2020002613 A CL 2020002613A CL 2020002613 A CL2020002613 A CL 2020002613A CL 2020002613 A1 CL2020002613 A1 CL 2020002613A1
Authority
CL
Chile
Prior art keywords
dll3
methods
chimeric
receptors
antigen
Prior art date
Application number
CL2020002613A
Other languages
English (en)
Inventor
Michael John Giffin
Melissa Thomas
Christopher Murawsky
Ryan Benjamin Case
Lawren Wu
Jed Wiltzius
Ruben Alvarez Rodriguez
Jun Feng
Original Assignee
Amgen Inc
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Kite Pharma Inc filed Critical Amgen Inc
Publication of CL2020002613A1 publication Critical patent/CL2020002613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Moléculas de unión a antígenos, receptores quiméricos y células inmunes modificadas para DLL3 de acuerdo con la invención. La invención se relaciona además con vectores, composiciones y métodos de tratamiento y/o detección usando las moléculas de unión a antígenos de DLL3 y células inmunes modificadas.
CL2020002613A 2018-04-10 2020-10-09 Receptores quiméricos de dll3 y métodos para su uso CL2020002613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862655725P 2018-04-10 2018-04-10

Publications (1)

Publication Number Publication Date
CL2020002613A1 true CL2020002613A1 (es) 2020-12-28

Family

ID=66248863

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020002613A CL2020002613A1 (es) 2018-04-10 2020-10-09 Receptores quiméricos de dll3 y métodos para su uso
CL2023000895A CL2023000895A1 (es) 2018-04-10 2023-03-28 Receptores quiméricos de dll3 y métodos para su uso
CL2023000896A CL2023000896A1 (es) 2018-04-10 2023-03-28 Receptores quiméricos de dll3 y métodos para su uso

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2023000895A CL2023000895A1 (es) 2018-04-10 2023-03-28 Receptores quiméricos de dll3 y métodos para su uso
CL2023000896A CL2023000896A1 (es) 2018-04-10 2023-03-28 Receptores quiméricos de dll3 y métodos para su uso

Country Status (27)

Country Link
US (1) US12012462B2 (es)
EP (1) EP3773912A1 (es)
JP (1) JP7479290B2 (es)
KR (1) KR102951376B1 (es)
CN (1) CN112334193A (es)
AR (1) AR114283A1 (es)
AU (2) AU2019251473A1 (es)
BR (1) BR112020020857A2 (es)
CA (1) CA3095920A1 (es)
CL (3) CL2020002613A1 (es)
CO (1) CO2020013392A2 (es)
CR (1) CR20200539A (es)
EA (1) EA202092417A1 (es)
IL (1) IL277735A (es)
JO (1) JOP20200259A1 (es)
MA (1) MA52203A (es)
MX (1) MX2020010753A (es)
MY (1) MY203383A (es)
PE (1) PE20211396A1 (es)
PH (1) PH12020551671A1 (es)
SA (1) SA520420301B1 (es)
SG (1) SG11202009923TA (es)
TW (1) TWI842703B (es)
UA (1) UA129466C2 (es)
UY (1) UY38182A (es)
WO (1) WO2019200007A1 (es)
ZA (1) ZA202006943B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901940B (zh) 2017-08-03 2025-10-21 美商安進公司 介白素-21突變蛋白及治療方法
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
TW202535924A (zh) * 2019-07-17 2025-09-16 大陸商南京傳奇生物科技有限公司 抗ｄｌｌ３嵌合抗原受體及其用途
CN115551887A (zh) * 2019-12-05 2022-12-30 维萨列克斯股份有限公司 通用细胞疗法的免疫逃逸机制的调节剂
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
US12606635B2 (en) 2020-03-12 2026-04-21 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
EP4313081A4 (en) * 2021-04-02 2025-04-09 Nanjing Legend Biotech Co., Ltd. MANIPULATED IMMUNE CELLS AND THEIR USES
WO2022237647A1 (zh) * 2021-05-08 2022-11-17 上海齐鲁制药研究中心有限公司 针对dll3的结合分子及其应用
KR20240006585A (ko) * 2021-05-10 2024-01-15 암젠 인크 Dll3 및 pd-1을 표적으로 하는 병용 요법을 위한 투여 요법
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4486775A2 (en) 2022-03-03 2025-01-08 Cambridge Enterprise Limited Therapeutic antibodies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
CA3262768A1 (en) * 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions containing them, and their uses
CN116003628A (zh) * 2022-08-15 2023-04-25 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
AU2024347905A1 (en) * 2023-09-26 2026-04-02 Legend Biotech Ireland Limited Dll3 binding moieties and uses thereof
WO2025082340A1 (zh) * 2023-10-16 2025-04-24 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
GB202402046D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
GB202402048D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025202653A1 (en) 2024-03-27 2025-10-02 Ucl Business Ltd T-cell therapy targetting mutant calreticulin
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
GB202412771D0 (en) 2024-08-30 2024-10-16 Cambridge Entpr Ltd Therapeutic molecules

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
IN2014CN02906A (es) * 2011-10-20 2015-07-03 Us Health
RU2014138474A (ru) * 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
SI3300745T1 (sl) 2013-02-15 2020-01-31 The Regents Of The University Of California Himerni antigenski receptor in postopki njihove uporabe
EP2968502B1 (en) 2013-03-14 2020-08-26 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN106459915A (zh) 2014-02-04 2017-02-22 凯德药业公司 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
KR102694879B1 (ko) * 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
KR102951376B1 (ko) 2026-04-13
AR114283A1 (es) 2020-08-12
AU2026200393A1 (en) 2026-04-09
IL277735A (en) 2020-11-30
ZA202006943B (en) 2025-08-27
SG11202009923TA (en) 2020-11-27
TWI842703B (zh) 2024-05-21
CA3095920A1 (en) 2019-10-17
KR20210018797A (ko) 2021-02-18
UY38182A (es) 2019-10-31
US12012462B2 (en) 2024-06-18
CR20200539A (es) 2021-07-01
TW202011999A (zh) 2020-04-01
CO2020013392A2 (es) 2020-11-10
AU2019251473A1 (en) 2020-10-22
MA52203A (fr) 2021-02-17
BR112020020857A2 (pt) 2021-01-19
CN112334193A (zh) 2021-02-05
JP7479290B2 (ja) 2024-05-08
MY203383A (en) 2024-06-26
PH12020551671A1 (en) 2021-06-07
US20210163621A1 (en) 2021-06-03
JOP20200259A1 (ar) 2020-10-11
UA129466C2 (uk) 2025-05-07
EA202092417A1 (ru) 2021-01-26
SA520420301B1 (ar) 2024-08-05
JP2021520788A (ja) 2021-08-26
CL2023000896A1 (es) 2023-11-03
MX2020010753A (es) 2021-01-29
WO2019200007A1 (en) 2019-10-17
EP3773912A1 (en) 2021-02-17
CL2023000895A1 (es) 2023-11-03
PE20211396A1 (es) 2021-07-27

Similar Documents

Publication Publication Date Title
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2022001873A1 (es) Receptores quiméricos y metodos de uso de los mismos
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA202092435A2 (ru) Моноклональные антитела против bcma
CL2024004076A1 (es) Receptores quiméricos de steap1 y métodos de uso de los mismos
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
EA201992027A1 (ru) Водный состав антитела против pd-l1
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA201991591A1 (ru) Нейтрализирующие анти-вич-1 антитела широкого спектра действия и способы их применения
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos